The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2005 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.
Dr. Dispenzieri presented data on a pre-clinical mouse study with the combination of Velcade and the radiopharmaceutical Quadramet (153 samarium EDTMP)
Dr. San Miguel presented preliminary data from a Phase I/II study in patients with relapsed/refractory myeloma of the novel therapy Aplidin, which is a marine-derived molecule with a novel mechanism of action
Dr. Wang presented data on a Phase I dose escalation multi-center clinical trial with the new drug Atiprimod for patients with relapsed/refractory myeloma
Dr. McGuirk reported on the first 70 patients enrolled in the AMD-3100 compassionate use program for poor stem cell mobilizers in need of stem cell harvest prior to autologous stem cell transplantation (SCT)
Dr. Van Ness presented his current work with the IMF Bank On A Cure program’s genetic data along with information about current and future research being conducted by the Bank On A Cure Team
print
back to top